CENTER FOR VALVE DISORDERS
Therapies Available via the Center for Valve Disorders
• Minimally invasive aortic , mitral , pulmonic and tricuspid valve repair and replacement
• Transcatheter valve-in-valve implantation for failed bioprosthetic valves in the aortic and mitral position
• MitraClip ® and transcatheter mitral valve repair ( TMVR ) for high surgical risk patients with severe mitral regurgitation
• Balloon mitral valvuloplasty for mitral stenosis
• Percutaneous left atrial appendage occlusion
• Percutaneous patent foramen ovale closure
• Percutaneous atrial septal defect closure
• Alcohol septal ablation for hypertrophic obstructive cardiomyopathy
TAVR In-Hospital Mortality Rate
( FY18 )
Femoral Access in TAVR Patients
( FY18 )
0.49 % 97 %
The Center for Valve Disorders at Baylor Scott & White Heart and Vascular Hospital – Dallas is among only a handful of centers in the United States studying the use of TAVR in low-risk and asymptomatic patients with aortic stenosis .
Minimally Invasive Aortic Valve Therapies
Baylor Scott & White Heart and Vascular Hospital – Dallas continues to be one of the top volume centers in the United States for commercial and research minimally invasive valve repair and replacement procedures . In fiscal year 2018 , the Center for Valve Disorders in Dallas remained one of the few centers in the United States to study the use of TAVR in low-risk and asymptomatic patients with aortic stenosis .
Since the early beginnings of TAVR , Robert Stoler , MD , medical director of the cardiac catheterization lab and co-director of the Division of Cardiology , and Paul Grayburn , MD , administrative director of the non-invasive lab , have conducted transcatheter mitral and aortic valve studies leading to FDA approval of new technologies for patients . Dr . Stoler and Dr . Grayburn are also known to proctor others in start-up TAVR programs internationally and nationally , sharing knowledge from the multidisciplinary Baylor Scott & White Heart and Vascular Hospital - Dallas campus program .
RESEARCH TRIALS
• Low-risk CoreValve / Evolut Trial
• Early TAVR for asymptomatic patients using the Edwards Sapien valve
• REFLECT Trial — Cerebral protection to reduce cerebral embolic lesions after transcatheter aortic valve implantation